SATE (aryl) phosphotriester series. I. Synthesis and biological evaluation

Area of Science:

• Medicinal Chemistry
• Virology
• Organic Synthesis

Background:

• Human Immunodeficiency Virus (HIV) remains a global health challenge.
• Developing effective antiviral therapies, particularly for drug-resistant strains, is crucial.
• Nucleoside reverse transcriptase inhibitors (NRTIs) are a cornerstone of HIV treatment.

Purpose of the Study:

• To synthesize novel phosphotriester derivatives of 3 '-azido-2 ',3 '-dideoxythymidine (AZT).
• To evaluate the in vitro anti-HIV activity of these derivatives.
• To assess the compounds' ability to deliver the active metabolite intracellularly, especially in thymidine kinase-deficient cells.

Main Methods:

• Chemical synthesis of AZT phosphotriester derivatives incorporating S-pivaloyl-2-thioethyl (tBuSATE) and L-tyrosine-derived aryl groups.
• Biological evaluation of anti-HIV activity using CEM cell lines, including thymidine kinase-deficient variants.
• Assessment of intracellular delivery and activation of the parent 5 '-mononucleotide.

Main Results:

• Several synthesized phosphotriester derivatives exhibited significant anti-HIV activity.
• The compounds demonstrated efficacy in thymidine kinase-deficient CEM cells.
• The results indicate successful intracellular delivery of the active 5 '-mononucleotide.

Conclusions:

• The novel phosphotriester derivatives of AZT are promising anti-HIV agents.
• These compounds overcome limitations associated with thymidine kinase deficiency.
• The findings support the potential of these derivatives as effective prodrugs for HIV therapy.